by Mark Chiang

马克·蒋

Share To

分享到

A radiopharmaceutical startup, Artbio, has raised $132 million in Series B funding to support the development of its prostate cancer treatment and expand its manufacturing capabilities. The company, led by former Novartis executive Emanuele Ostuni, is advancing a new medicine into early clinical trials as part of its efforts to compete in the growing field of targeted cancer therapies..

一家名为Artbio的放射性药物初创公司已经筹集了1.32亿美元的B轮融资，以支持其前列腺癌治疗药物的开发并扩大生产能力。这家由前诺华高管埃马努埃莱·奥斯塔尼领导的公司，正在将一种新药推进到早期临床试验阶段，作为其在不断增长的靶向癌症治疗领域竞争的一部分。

The funding will enable Artbio to test its experimental drug, which aims to rival Pluvicto, a prostate cancer treatment developed by Novartis. Alongside clinical testing, the company is also focusing on building a manufacturing network to support the production and distribution of its radiopharmaceuticals.

这笔资金将使Artbio能够测试其试验药物，该药物旨在与诺华开发的前列腺癌治疗药物Pluvicto竞争。除了临床测试，该公司还专注于建立一个生产网络，以支持其放射性药物的生产和分销。

This investment marks a significant step for Artbio as it seeks to establish itself in the competitive oncology market..

这项投资标志着Artbio在寻求在竞争激烈的肿瘤市场中确立自己的地位方面迈出了重要一步。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: July 29, 2025

日期：2025年7月29日

Related posts:

相关内容：

Drug Patent Watch Outlines Strategies for Biosimilar Switching Amidst Increasing Availability

药物专利观察：随着生物仿制药供应增加，制定转换策略

Millipore Sigma to Impose Tariff Surcharge on All U.S.-Bound Orders

默克密理博将对所有运往美国的订单征收关税附加费

Meta-Analysis Reveals Correlation Between RSV Viral Load Dynamics and Symptom Progression in Human Challenge Studies

荟萃分析揭示了RSV病毒载量动态与人体挑战研究中症状进展的相关性

Independent Pharmacies Gain Ground in Exclusive Specialty Pharmacy Networks, Reports DCI

独立药房在独家专业药房网络中取得进展，DCI报告称。

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·江

Related Post

相关内容

News Flash

新闻快讯

Fulcrum Therapeutics Study Shows Experimental Pill May Target Underlying Causes of Sickle Cell Disease

Fulcrum Therapeutics研究显示实验性药物可能针对镰状细胞病的根本原因

2025-07-29

2025年7月29日